Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001422848-26-000023·Capital Research Global Investors
Schedule 13G ownership disclosure
VERTEX PHARMACEUTICALS INC COM
Common Stock · CUSIP: 92532F100
Event date: 2025-12-31
- Filing-level shares
- 17,319,044.00
- Percent of class
- 6.8%
- Capital Research Global Investors
Shares: 17,319,044.00 · Class: 6.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001422848-26-000023
- Form type
- SCHEDULE 13G/A
- Filer
- Capital Research Global Investors
- CIK
- CIK 1422848
- Filed
- Feb 12, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership